Fatigue is costing more than you think
Identify undiagnosed sleep apnea across your workforce and reduce its impact
Undiagnosed OSA leads to

.png)
Better sleep drives measurable business outcomes
Sleep apnea is one of the most under-diagnosed conditions in the US workforce, and it costs employers in three direct ways: higher medical claims for downstream conditions like hypertension, diabetes, and cardiovascular disease, lost productivity from chronic fatigue and impaired concentration, and increased absenteeism and disability risk. Research suggests untreated sleep apnea costs the US economy roughly $150 billion annually, with employers absorbing a meaningful share of that through claims and lost work output.
Research suggests obstructive sleep apnea affects between 10 and 30 percent of adults depending on the population, and roughly 80 percent of moderate-to-severe cases remain undiagnosed. In a workforce of 1,000 employees, that means 100 to 300 individuals are likely to be living with the condition, and most don't know it. The gap is widest in employees who don't fit traditional risk profiles, including women and non-obese employees with anatomical risk factors.
Soliish provides AI-powered sleep apnea risk screening that employees can complete privately on any smartphone, in 60 seconds, with no app to download. Employees who screen at elevated risk are automatically connected to a licensed sleep telehealth provider for evaluation and, if appropriate, diagnosis and prescription. The full pathway, from screening to therapy, runs on the Soliish platform with HIPAA-compliant data handling throughout.
Employees access Soliish through a secure link delivered by email, SMS, or a benefits portal. The AI selfie scan and brief intake take about 60 seconds. Results are delivered privately to the employee, never to the employer. If elevated risk is identified, the employee can self-schedule a telehealth consultation directly from the platform. Diagnosis, prescription, and therapy fulfilment happen through licensed providers in the Soliish network, with no additional steps required from the employer.
No. Individual employee health data, including screening results, diagnoses, and treatment information, is never shared with the employer. Soliish operates as a HIPAA-compliant medical platform, and all clinical data flows between the employee and licensed providers. Employers receive only aggregated, de-identified reporting on programme engagement and population-level outcomes, similar to how other clinical benefits report performance.
Soliish integrates with most major benefits administration platforms, wellness vendors, and employee communication channels. The screening and care pathway can be deployed as a standalone benefit, embedded into an existing wellness portal, or activated through targeted campaigns to specific employee segments. Most enterprise rollouts go live within 30 to 60 days, with no hardware procurement and no new clinical infrastructure required.
Wellness apps and consumer sleep trackers raise general awareness but don't connect employees to clinical care. Soliish is a medical platform: the AI selfie scan generates a clinical risk signal, and elevated-risk employees are routed directly to licensed sleep physicians for evaluation, diagnosis, and prescription. The pathway ends in clinical outcomes, not engagement metrics. For procurement, this matters because the cost-impact case for sleep apnea programmes depends on employees actually reaching diagnosis and treatment.
Studies indicate that treated sleep apnea reduces downstream medical claims for cardiovascular and metabolic conditions, lowers absenteeism, improves measurable productivity metrics, and reduces accident rates in safety-sensitive roles. The ROI strengthens when the programme captures employees who would otherwise remain undiagnosed for years, because earlier identification compounds savings over time. Soliish provides employer-specific ROI modelling during the evaluation process, based on workforce size, demographics, and current benefits structure.